# A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

> **NCT07690826** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 252 (estimated)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** HRS-4729 Injection
- **DRUG:** HRS-4729 Injection
- **DRUG:** HRS-4729 Injection
- **DRUG:** HRS-4729 Injection;
- **DRUG:** HRS-4729 Injection;
- **DRUG:** HRS-4729 Injection;
- **DRUG:** HRS-4729 Injection Placebo

## Key facts

- **NCT ID:** NCT07690826
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-03
- **Final completion:** 2027-07
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07690826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07690826, "A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07690826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*